Literature DB >> 8729973

ras and p53 genes in male breast cancer.

P J Dawson1, K R Schroer, S R Wolman.   

Abstract

We have studied the roles of Ki-ras oncogene and p53 tumor suppressor gene in a series of 20 cases of male breast cancer and one papilloma of the male breast. Ki-ras was detected in 50-microns sections after digestion with proteinase K and SDS. DNA was amplified by polymerase chain reaction, dot blotted, and mutations were screened with labeled ras mutation-specific oligonucleotides. Wild-type and mutant p53 protein were detected with antibodies CM1 and DO7, using the avidin-biotin-peroxidase method. Two of 17 carcinomas showed Ki-ras mutations, both in codon 12 (gly --> lys and gly --> arg). Five of 20 male breast cancers (25%), including one large intraductal carcinoma, expressed mutant p53 protein. Although the incidence of mutant p53 expression in male breast cancer is similar to that in women, Ki-ras mutations are not significantly increased.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8729973

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  4 in total

Review 1.  Male breast cancer: is the scenario changing.

Authors:  Kaiyumars B Contractor; Kanchan Kaur; Gabriel S Rodrigues; Dhananjay M Kulkarni; Hemant Singhal
Journal:  World J Surg Oncol       Date:  2008-06-16       Impact factor: 2.754

2.  PIK3CA mutations are frequently observed in BRCAX but not BRCA2-associated male breast cancer.

Authors:  Siddhartha Deb; Hongdo Do; David Byrne; Nicholas Jene; Alexander Dobrovic; Stephen B Fox
Journal:  Breast Cancer Res       Date:  2013       Impact factor: 6.466

3.  Mutational profiling of familial male breast cancers reveals similarities with luminal A female breast cancer with rare TP53 mutations.

Authors:  S Deb; S Q Wong; J Li; H Do; J Weiss; D Byrne; A Chakrabarti; T Bosma; A Fellowes; A Dobrovic; S B Fox
Journal:  Br J Cancer       Date:  2014-12-09       Impact factor: 7.640

4.  Molecular analysis of a male breast cancer patient with prolonged stable disease under mTOR/PI3K inhibitors BEZ235/everolimus.

Authors:  A Rose Brannon; Melissa Frizziero; David Chen; Jennifer Hummel; Jorge Gallo; Markus Riester; Parul Patel; Wing Cheung; Michael Morrissey; Carmine Carbone; Silvia Cottini; Giampaolo Tortora; Davide Melisi
Journal:  Cold Spring Harb Mol Case Stud       Date:  2016-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.